Since 2008, Ms. Caplan has been Chief Executive Officer of Kamedis, a company focused on utilizing plant extracts for dermatology purposes. From 2004 to 2007, Ms. Caplan was Chief Executive Officer of GammaCan, a company focused on the use of immunoglobulins for the treatment of cancer. During the previous five years, Ms. Caplan has been a director of the following companies: Opticul Ltd., a company involved with optic based bacteria classification; Inmotion Ltd., a company involved with self-propelled disposable colonoscopies; Nehora Photonics Ltd., a company involved with non-invasive blood monitoring; Ocure Ltd., a company involved with wound management; Eve Medical Ltd., a company involved with hormone therapy for Menopause and PMS; and Biotech Investment Corp., a company involved with prostate cancer diagnostics. Ms. Caplan has a M.Sc. in bio-medical engineering from Tel-Aviv University specialized in signal processing; management for engineers from Tel-Aviv University specialized in business development; and a B.Sc. in mechanical engineering from the Technion Institute of Technology specialized in software and cad systems.
Scott P. Carmer
CEO, Orgenesis North America
Mr. Carmer has more than 25 years of diverse experience within the pharmaceutical and biotech industries. Before joining Orgenesis, he led the US Specialty Care Division of AstraZeneca, and had responsibility for the company’s portfolio of specialty care biopharmaceutical products. Prior to his role at AZ, he served as Executive Vice President, Commercial Operations of MedImmune (which was acquired by AstraZeneca). Before his time at AZ/MedImmune, Mr. Carmer was Vice President, Rheumatology Sales & Marketing for Genentech, where he was responsible for the US launches of Rituxan and ACTEMRA in Rheumatoid Arthritis. He joined Genetech from Amgen, Inc., where he last held the role of Global Therapeutic Area Head for Bone and Metabolic Disorders, and was responsible for global development and commercialization strategies for denosumab (Xgeva and Prolia). Mr. Carmer began his career at GSK, where he held various positions of increasing responsibility in the areas of sales, marketing, strategic pricing and business development.
Sarah Ferber Ph.D.
Chief Science Officer & Founder
Prof. Sarah Ferber studied biochemistry at the Technion under the supervision of Professor Avram Hershko and Professor Aaron Ciechanover, winners of the Nobel Prize in Chemistry in 2004. She completed a post-doctoral fellowship at the Joslin Diabetes Center at Harvard Medical School. Prof. Ferber's breakthrough discovery suggested that humans carry their own 'stem-cells' throughout adulthood, thus obviating the need for embryonic stem cells for generating an organ in need. Most of the research was conducted in Prof. Ferber’s lab, in the Endocrine Research Lab at the Sheba Medical Center, and currently employs 11 scientists. Prof. Sarah Ferber received TEVA, LINDNER, RUBIN and WOLFSON awards for this research. Prof. Ferber’s research work has been funded over the past 10 years by the Juvenile Diabetes Research Foundation (JDRF), the Israel Academy of Science foundation (ISF) and D-Cure, a non-profit organization that promotes and funds scientific research in Israel, aimed at finding a cure and better treatments for diabetes (together, over US$4M)
Joseph Tenne CPA, MBA
20+ years of senior management experience with international public and private companies. Previously served as CFO of Ormat Technologies (NYSE: ORA), a U.S. company listed on the New York Stock Exchange, and as CFO of Ormat Industries, an Israeli company listed on the Tel Aviv Stock Exchange. Mr. Tenne currently serves as an independent financial expert director and the chairman of the audit and compensation committees for Enzymotec (NASDAQ: ENZY) and a member of the audit and compensation committees of AudioCodes (NASDAQ: AUDC).